Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
49Citations signalées, ce qui n’est pas une note de qualité
72Institutions déclarées
4Pays d’affiliation déclarés
Rattachement africain : cn, us, tw, sg. Niveau de preuve : code pays fourni par la source.
Résumé indisponible. Les résultats de l’étude ne doivent pas être déduits de son seul titre.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
- Date Crossref
- 01/07/2025
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Les institutions déclarées
Sun Yat-sen UniversityFudan UniversityZhongshan HospitalThe First Affiliated Hospital, Sun Yat-sen UniversityMedical Center HospitalShandong Tumor HospitalShandong First Medical UniversityAnhui Provincial HospitalJilin Province Tumor HospitalSichuan Cancer HospitalLiaoning Cancer Hospital & InstituteSichuan UniversityWest China Hospital of Sichuan UniversityNanchang UniversitySecond Affiliated Hospital of Nanchang UniversityHunan Cancer HospitalHarbin Medical UniversityThird Affiliated Hospital of Harbin Medical UniversityFirst Affiliated Hospital of Gannan Medical UniversityWuhan Union HospitalArmy Medical UniversitySouthwest HospitalTongji HospitalHuazhong University of Science and TechnologyDaping HospitalChinese Academy of Medical Sciences & Peking Union Medical CollegePeking Union Medical College HospitalCentral South UniversityXiangya Hospital Central South UniversityFirst Affiliated Hospital of Bengbu Medical CollegeWenzhou Medical UniversityFirst Affiliated Hospital of Wenzhou Medical UniversityHuawei Technologies (China)Hangzhou Red Cross HospitalTianjin Medical University Cancer Institute and HospitalNanfang HospitalSouthern Medical UniversityWuhan UniversityZhongnan Hospital of Wuhan UniversityNantong Tumor HospitalAnhui Medical UniversitySecond Affiliated Hospital of Anhui Medical UniversityChangchun 208 HospitalHainan General HospitalShantou UniversityYue Bei People's HospitalNanjing Drum Tower HospitalChanghua Christian HospitalHubei Cancer HospitalChinese People's Liberation ArmyZhejiang Provincial People's HospitalZhejiang Cancer HospitalMackay Memorial HospitalFirst Affiliated Hospital of Zhengzhou UniversityFirst Affiliated Hospital Zhejiang UniversitySun Yat-sen Memorial HospitalFirst Affiliated Hospital of Nanchang UniversityTan Tock Seng HospitalHenan Cancer HospitalThe Affiliated Yongchuan Hospital of Chongqing Medical UniversityChongqing Medical UniversityFirst Affiliated Hospital of Xi'an Jiaotong UniversityNational Cancer Centre SingaporeFirst Hospital of Lanzhou UniversityLanzhou UniversityXuzhou Medical CollegeKaohsiung Medical University Chung-Ho Memorial HospitalPeking UniversityPeking University Cancer HospitalQingdao UniversityAffiliated Hospital of Qingdao UniversityFirst People's Hospital of Foshan
Une affiliation ne permet pas de déduire la nationalité d’un auteur.
Les sujets associés
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and BiomarkersCholangiocarcinoma and Gallbladder Cancer Studies